Adults with knee osteoarthritis may need to temper expectations about anti-inflammatory approaches, as new evidence challenges a promising treatment strategy. Despite decades of research suggesting inflammation drives osteoarthritis pain, a precision medicine approach targeting inflamed joints has shown disappointing results in practice. Australian researchers tested diacerein, an interleukin-1β blocker, specifically in patients with both severe knee pain and visible joint inflammation on MRI scans. This targeted approach represented ideal conditions for anti-inflammatory therapy to succeed. The 24-week trial enrolled 262 participants with clinically confirmed osteoarthritis, substantial pain levels, and effusion-synovitis visible on magnetic resonance imaging. Participants received either diacerein 50mg daily (increased to twice daily) or placebo. Pain reduction measured approximately 20mm on a 100mm visual scale in both groups, with no meaningful difference between active treatment and placebo. This finding carries broader implications for osteoarthritis management beyond this single drug. The inflammatory phenotype concept—identifying patients whose arthritis is driven primarily by inflammation—has been a cornerstone of personalized medicine approaches in rheumatology. Yet even when researchers carefully selected patients with visible inflammation and used a targeted anti-inflammatory agent, the intervention failed to outperform placebo. This suggests either that synovial inflammation may be more consequence than cause of osteoarthritis pain, or that current anti-inflammatory strategies remain insufficient. For the millions managing knee osteoarthritis, this reinforces the complexity of the condition and the continued need for multimodal approaches combining physical therapy, weight management, and symptomatic relief rather than relying on single-target pharmaceutical interventions.